Since epidemiologic data have highlighted the positive effects of metformin to reduce cancer
incidence and mortality, many in vitro and in vivo studies as well as a large number of …

Type 2 diabetes mellitus is associated with increased risk of malignancy (mainly cancer of
the pancreas, breast, colon, endometrium and bladder). In addition, there is evidence that …

Metformin, an inexpensive, well-tolerated oral agent that is commonly used in the first-line
treatment for type 2 diabetes, has become the focus of intense research as a potential …

Metformin, a biguanide derivative that is widely used for treating type 2 diabetes mellitus,
has recently been shown to exert potential anticancer effects. Many retrospective data and …

Metformin is considered, in conjunction with lifestyle modification, as a first-line treatment
modality for type 2 diabetes mellitus (DM). Recently, several clinical studies have reported …

Introduction Metformin, an oral hypoglycemic agent, was introduced in the clinical practice
for the treatment of type 2 diabetes mellitus more than a half-century ago. Over the years …

Metformin is widely used in the treatment of diabetes mellitus type 2 where it reduces insulin
resistance and diabetes-related morbidity and mortality. Population-based studies show that …

Metformin is the most widely used antidiabetic drug in the world, and there is increasing
evidence of a potential efficacy of this agent as an anticancer drug. First, epidemiological …

Epidemiological studies have shown that metformin, a first line therapeutic agent for
diabetes mellitus, reduced the risk of developing various malignancies. Several preclinical …

Type 2 diabetes mellitus is a rising cause of cardiovascular morbidity and mortality. A
number of studies have also identified diabetic patients as having increased risk for the …